Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Background: Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in an external cohor...

Full description

Bibliographic Details
Main Authors: Foteinos-Ioannis Dimitrakopoulos, Giannis Mountzios, Petros Christopoulos, Thomas Papastergiou, Mariam Elshiaty, Lea Daniello, Elefterios Zervas, Sofia Agelaki, Epaminondas Samantas, Adamantia Nikolaidi, Ilias Athanasiadis, Sofia Baka, Konstantinos Syrigos, Athina Christopoulou, Evangelos Lianos, Konstantinos Samitas, Nikolaos Tsoukalas, Eleni-Isidora Perdikouri, George Oikonomopoulos, Anastasia Kottorou, Foteini Kalofonou, Thomas Makatsoris, Angelos Koutras, Vasileios Megalooikonomou, Haralabos Kalofonos
Format: Article
Language:English
Published: SAGE Publishing 2022-09-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221122728

Internet

https://doi.org/10.1177/17588359221122728

Similar Items